Trial Profile
Discontinuation study of nilotinib in patients with chronic myeloid leukemia who have maintained complete molecular remission for at least 2 years: the prospective, multicenter stop study in Japan adult leukemia study group
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 30 May 2017
At a glance
- Drugs Dasatinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- Acronyms JALSG-D-STOP216
- 29 Nov 2016 New trial record